

Adult CIRB - Early Phase Emphasis Meeting Agenda

May 5, 2020

I Continuing Review

9466, Phase I/II study of dabrafenib, trametinib, and navitoclax in BRAF mutant melanoma (Phase I and II) and other solid tumors (Phase I only) (Protocol Version Date 11/26/19)

II Continuing Review

9706, Randomized phase II study to assess the role of Nivolumab as single agent to eliminate minimal residual disease and maintain remission in acute myelogenous leukemia (AML) patients after chemotherapy (REMAIN Trial) (Protocol Version Date 09/24/19)

III Continuing Review

9898, A Phase I Trial of AZD9291 and Nectinmab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor (Protocol Version Date 09/23/19)

IV Continuing Review

S1320, A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma (Protocol Version Date 12/05/19)
